Connor, Clark & Lunn Investment Management Ltd. Homology Medicines, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$21.8 Billion
Q1 2024

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$0.84 - $1.43 $68,034 - $115,821	-80,994 Reduced 87.46%	11,612 $13,000
Q2 2023 Aug 10, 2023	SELL	$0.83 - $1.12 $66,042 - $89,117	-79,569 Reduced 46.21%	92,606 $81,000
Q1 2023 May 09, 2023	SELL	$0.91 - $1.69 $22,568 - $41,913	-24,801 Reduced 12.59%	172,175 $177,000
Q4 2022 Feb 10, 2023	SELL	$1.09 - $2.04 $39,049 - $73,083	-35,825 Reduced 15.39%	196,976 $248,000
Q3 2022 Nov 10, 2022	BUY	$1.55 - $3.01 $8,686 - $16,868	5,604 Added 2.47%	232,801 $375,000

Q2 2022 Aug 05, 2022	BUY	$1.39 - $3.12 $43,483 - $97,602	31,283 Added 15.97%	227,197 $448,000
Q1 2022 May 12, 2022	SELL	$2.6 - $4.17 $19,890 - $31,900	-7,650 Reduced 3.76%	195,914 $596,000
Q4 2021 Feb 10, 2022	BUY	$3.64 - $7.78 $333,733 - $713,309	91,685 Added 81.95%	203,564 $741,000
Q3 2021 Nov 12, 2021	BUY	$6.01 - $8.71 $170,040 - $246,432	28,293 Added 33.85%	111,879 $880,000
Q2 2021 Aug 12, 2021	BUY	$6.02 - $9.64 $503,187 - $805,769	83,586 New	83,586 $608,000

Others Institutions Holding FIXX

# of Institutions

Shares Held

66.2K

Call Options Held

Put Options Held

View Full List

About Homology Medicines, Inc.

Ticker FIXX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 57,402,000
Description
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nucleas...

More about FIXX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account